



New first-line treatment for recurrent or metastatic squamous cell carcinoma of head and neck: does one size fit all?

Naomi Kiyota^{1,2}, Yoshinori Imamura²

¹Kobe University Hospital Cancer Center, ²Department of Medical Oncology and Hematology, Kobe University Hospital, Hyogo, Japan

Correspondence to: Naomi Kiyota, MD, PhD. Kobe University Hospital Cancer Center, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, Hyogo 650-0017, Japan. Email: nkiyota@med.kobe-u.ac.jp.

Provenance and Peer Review: This article was commissioned by the editorial office, *Therapeutic Radiology and Oncology*. The article did not undergo external peer review.

Comment on: Burtness B, Harrington KJ, Greil R, *et al.* Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. *Lancet* 2019;394:1915-28.

Received: 08 January 2020; Accepted: 23 March 2020; Published: 30 June 2020.

doi: 10.21037/tro.2020.03.02

View this article at: <http://dx.doi.org/10.21037/tro.2020.03.02>

Background

According to cancer statistics for 2012 (GLOBOCAN), the global incidence of HNC in that year stood at around 680,000, with 390,000 of these cases occurring in Asian countries. Around 240,000 Asian people died from HNC, accounting for 5.5% of global cancer deaths (1). Patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) have a poor prognosis. Treatment goals are limited, but include prolongation of survival, palliation of existing symptoms and prevention of new cancer-related symptoms. In particular, systemic chemotherapy has only a modest impact on outcome in these patients (2), and median survival in reported Phase III randomized trials ranges from 6 to 9 months (3-8). Platinum-based chemotherapy remains the standard, and although combination therapy has shown higher response rates, no other regimen has demonstrated a survival advantage over cisplatin monotherapy. In their randomized Phase III trial of cisplatin or carboplatin plus 5-FU (PF/CF) with or without cetuximab against PF/CF for R/M SCCHN (EXTREME Study), Vermorken *et al.* reported that the hazard ratio for overall survival (OS) of PF/CF plus cetuximab to PF/CF alone was 0.80 [95% confidence interval (CI), 0.64–0.99]. Median OS was 10.1 months for PF/CF plus cetuximab versus 7.4 months for PF/CF alone (P=0.04) (9). From this result, PF/CF + cetuximab, the so-called EXTREME regimen, has been

the standard first line chemotherapy for patients with R/M SCCHN. For platinum-refractory R/M SCCHN, the anti-PD-1 antibodies nivolumab and pembrolizumab demonstrated a survival benefit in the pivotal Phase III trials (CheckMate141, KEYNOTE-040) (10,11). Recently, however, Burtness *et al.* reported the practice-changing results of a Phase III trial (KEYNOTE-048; KN-048) which compared the EXTREME regimen with pembrolizumab alone or PF/CF plus pembrolizumab for patients with previously untreated R/M SCCHN (12).

KEYNOTE-048

KN-048 was a randomized phase III trial of patients with previously untreated R/M SCCHN. Patients were stratified by PD-L1 expression (TPS: tumor proportion score), p16 status and performance status and randomized in a 1:1:1 ratio to pembrolizumab alone, PF/CF plus pembrolizumab and the EXTREME regimen as the standard arm. The primary endpoints were OS and progression-free survival (PFS) in the intention-to-treat (ITT) population (12). The statistical methods were markedly complex, and likely left many oncologists uncertain of their validity, and wondering whether they represent a suitable direction for oncology to pursue. There were 14 primary hypotheses: the superiority of pembrolizumab alone and of PF/CF plus pembrolizumab versus the EXTREME regimen for OS and PFS with a PD-L1 CPS (combined positive score) of

20 or more, CPS of 1 or more, and the total population; and the non-inferiority (non-inferiority margin: 1.2) of pembrolizumab alone and of PF/CF plus pembrolizumab versus the EXTREME regimen for overall survival in the total population. Of these 14 primary hypotheses, six were tested first, in parallel: superiority of pembrolizumab alone and of PF/CF plus pembrolizumab versus the EXTREME regimen for OS and PFS in PD-L1 CPS ≥ 20 , superiority of PF/CF plus pembrolizumab versus EXTREME regimen for PFS and non-inferiority of PF/CF plus pembrolizumab versus EXTREME regimen for OS. The remaining eight hypotheses were then tested hierarchically to control for an overall one-sided type I error of 0.025 based on the orders of CPS ≥ 20 , ≥ 1 and ITT. The pre-defined treatment outcomes are summarized in *Table 1*. From the results, pembrolizumab alone was superior to the EXTREME regimen in the population of CPS ≥ 20 and ≥ 1 and non-inferior to the EXTREME regimen in the ITT population, while PF/CF plus pembrolizumab was superior to the EXTREME regimen in the populations of CPS ≥ 20 , ≥ 1 and ITT. The Food and Drug Administration (FDA) and European Medicines Agency (EMA) consequently approved pembrolizumab alone for previously untreated R/M SCCHN in patients expressing PD-L1 (CPS) ≥ 1 , and approved PF/CF plus pembrolizumab for previously untreated R/M SCCHN, albeit that EMA restricted this approval to patients expressing PD-L1 (CPS) ≥ 1 .

However, a detailed analysis of KN-048 raises questions about whether pembrolizumab alone or PF/CF plus pembrolizumab can take all places of the EXTREME regimen. This is because the KN-048 paper provides no information about the efficacy of pembrolizumab alone or PF/CF plus pembrolizumab in the $1 \leq \text{CPS} < 20$ and CPS < 1 population. From the summarized results of *Table 1*, we assume that the robust effectiveness in the CPS ≥ 20 population, which generally accounts for around 40% of these patients, cast a positive result over the total population. If so, applying the results of KN-048 into clinical practice should be done with care, because the benefit of pembrolizumab alone or PF/CF plus pembrolizumab against the EXTREME regimen may be less than expected for the CPS 1–19 and CPS < 1 population. These questions are further addressed in the EMA (European Medicines Agency) assessment report (Procedure No. EMEA/H/C/003820/II/0065, [https://www.ema.europa.eu/en/documents/variation-report/keytruda-h-c-3820-ii-0065-epar-assessment-report-](https://www.ema.europa.eu/en/documents/variation-report/keytruda-h-c-3820-ii-0065-epar-assessment-report-variation_en.pdf)

[variation_en.pdf](https://www.ema.europa.eu/en/documents/variation-report/keytruda-h-c-3820-ii-0065-epar-assessment-report-variation_en.pdf)), which describes the post-hoc exploratory analysis of KN-048 focusing on the CPS 1–19 and CPS < 1 population, summarized in *Table 2*. For the CPS 1–19 population, median OS of pembrolizumab alone and the EXTREME regimen were closely similar, while the overall response rate (ORR) of pembrolizumab alone was lower than that of EXTREME regimen. On the other hand, median OS of PF/CF plus pembrolizumab was better than that of the EXTREME regimen and ORR of PF/CF plus pembrolizumab was closely similar to it. In the CPS < 1 population, median OS of pembrolizumab alone appeared to be worse than that of the EXTREME regimen and ORR was much lower. In contrast, the median OS of PF/CF plus pembrolizumab was closely similar to that of the EXTREME regimen while ORR appeared to be lower. These findings show that pembrolizumab alone most benefits the CPS ≥ 20 population while PF/CF plus pembrolizumab most benefits the CPS ≥ 1 population.

With regard to adverse events, pembrolizumab alone had a better safety profile than the PF/CF plus pembrolizumab or EXTREME regimens, with rates of any grade 3 or worse adverse events of 55% with pembrolizumab alone, 85% with PF/CF plus pembrolizumab and 83% with the EXTREME regimen. In terms of adverse events of interest (so-called immune-related adverse events), events of any grade occurred in 31% with pembrolizumab alone and 26% with PF/CF plus pembrolizumab. There were no new safety concerns for pembrolizumab or PF/CF plus pembrolizumab.

Combining the above efficacy and safety information for each treatment option, and considering patient condition and disease status, we propose a new treatment algorithm for patients with previously untreated SCCHN.

For patients with previously untreated platinum-sensitive R/M SCCHN:

- (I) Asymptomatic and stable patients:
 - (i) CPS ≥ 20 : pembrolizumab alone;
 - (ii) $1 \leq \text{CPS} < 20$: PF/CF plus pembrolizumab or pembrolizumab alone;
 - (iii) CPS < 1 : PF/CF plus pembrolizumab or EXTREME regimen;
- (II) Symptomatic or progressive patients:
 - (i) CPS ≥ 20 : PF/CF plus pembrolizumab or pembrolizumab;
 - (ii) $1 \leq \text{CPS} < 20$: PF/CF plus pembrolizumab;
 - (iii) CPS < 1 : EXTREME regimen or PF/CF plus pembrolizumab.

Table 1 Summary of the pre-defined outcomes of KEYNOTE-048 from primary manuscript (12)

Treatment arms	Pembrolizumab vs. EXTREME			Pembrolizumab plus chemotherapy vs. EXTREME		
	CPS ≥20	CPS ≥1	ITT	CPS ≥20	CPS ≥1	ITT
Treatment	P (N=133) E (N=122)	P (N=257) E (N=255)	P (N=301) E (N=300)	PC (N=126) E (N=110)	PC (N=242) E (N=235)	PC (N=281) E (N=278)
OS (median), M	14.9 10.7	12.3 10.3	11.6 10.7	14.7 11.0	13.6 10.4	13.0 10.7
HR (95% CI)	0.61 (0.44–0.78)	0.78 (0.64–0.96)	0.83 (0.70–0.99)	0.60 (0.45–0.82)	0.65 (0.53–0.80)	0.72 (0.60–0.87)
P value	0.0007*	0.0086*	0.0199†	0.00044*	0.00002*	0.00025*
PFS (median), M	3.4 5.0	3.2 5.0	2.3 5.2	5.8 5.2	5.0 5.0	4.9 5.1
HR (95% CI)	0.99 (0.75–1.29)	1.16 (0.96–1.39)	1.34 (1.13–1.59)	0.73 (0.55–0.97)	0.82 (0.67–1.00)	0.93 (0.78–1.11)
P value	0.46791**	0.89580**	0.99830**	0.0162**	0.03697**	0.21211**
ORR	23% 36%	19% 34%	16% 36%	42% 38%	36% 35%	35% 36%

*, superiority; †, non-inferiority; **, not significant. CPS, combined positive score; ITT, intention-to treat; P, pembrolizumab; E, EXTREME regimen; PC, pembrolizumab plus chemotherapy; OS, overall survival; M, months; HR, hazard ratio; PFS, progression-free survival; NS, not significant; ORR, overall response rate.

Table 2 Summary of the post-hoc analysis of KEYNOTE-048 from EMA assessment report

Treatment arms	Pembrolizumab vs. EXTREME			Pembrolizumab plus chemotherapy vs. EXTREME		
	CPS ≥20	1 ≤ CPS <20	CPS <1	CPS ≥20	1 ≤ CPS <20	CPS <1
Treatment	P (N=133) E (N=122)	P (N=124) E (N=133)	P (N=44) E (N=45)	PC (N=126) E (N=110)	PC (N=116) E (N=125)	PC (N=39) E (N=43)
OS (median), M	14.8 10.7	10.8 10.1	7.9 11.3	14.7 11.0	12.7 9.9	11.3 10.7
HR (95% CI)	0.58 (0.44–0.78)	0.86 (0.66–1.12)	1.51 (0.96–2.37)	0.60 (0.45–0.82)	0.71 (0.54–0.94)	1.21 (0.76–1.94)
P value	0.00010*	0.12827	0.96241	0.00044*	0.00726	0.78932
PFS (median), M	3.4 5.3	2.2 4.9	2.1 6.2	5.8 5.2	4.9 4.9	4.7 6.2
HR (95% CI)	0.99 (0.76–1.29)	1.25 (0.96–1.61)	4.31 (2.63–7.08)	0.73 (0.55–0.97)	0.93 (0.71–1.21)	1.46 (0.93–2.30)
P value	0.46791	0.95093	1.00000	0.0162**	0.29189	0.94898
ORR	23% 36%	14% 33%	4.5% 42%	42% 38%	29% 33%	30% 39%

*, superiority; **, not significant. CPS, combined positive score; ITT, intention-to treat; P, pembrolizumab; E, EXTREME regimen; PC, pembrolizumab plus chemotherapy; OS, overall survival; M, months; HR, hazard ratio; PFS, progression-free survival; NS, not significant; ORR, overall response rate.

Conclusions

Burtness *et al.* demonstrated better treatment outcomes with pembrolizumab alone and PF/CF plus pembrolizumab than previous standard treatment with the EXTREME regimen in patients with previously untreated platinum-sensitive R/M SCCHN. However, the effectiveness of pembrolizumab alone and PF/CF plus pembrolizumab vary according to PD-L1 status (CPS). Hence, this new evidence should only be applied after close consideration of clinical situation and patient preference.

Acknowledgments

Funding: None.

Footnote

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at <http://dx.doi.org/10.21037/tro.2020.03.02>). NK reports grants from research funding from ONO PHARMACEUTICAL Co., Ltd., grants from research funding from Bristol-Meyers Squibb, grants from research funding from Astra Zeneca Co., Ltd., grants from research funding from Pfizer Co., Ltd., grants from research funding from Chugai Pharmaceutical Co., Ltd., during the conduct of the study; grants from research funding from Rakuten Medical, outside the submitted work; and honoraria from ONO PHARMACEUTICAL Co., Ltd., Bristol-Meyers Squibb, Merck Biopharma, Astra-Zeneca Co., Ltd., Merck Sharp & Dohme, Eisai and Bayer. NK also serves as the unpaid editorial board member of *Therapeutic Radiology and Oncology* from Dec 2018 to Nov 2020. YI has no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the

formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

References

1. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. [database on the Internet]. International Agency for Research on Cancer; 2013. 2012. Available online: <http://globocan.iarc.fr>
2. Morton RP, Rugman F, Dorman EB, et al. Cisplatin and bleomycin for advanced or recurrent squamous cell carcinoma of the head and neck: a randomised factorial phase III controlled trial. *Cancer Chemother Pharmacol* 1985;15:283-9.
3. Jacobs C, Lyman G, Velez-Garcia E, et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. *J Clin Oncol* 1992;10:257-63.
4. Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. *J Clin Oncol* 1992;10:1245-51.
5. Forastiere AA, Leong T, Rowinsky E, et al. Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group Study E1393. *J Clin Oncol* 2001;19:1088-95.
6. Gibson MK, Li Y, Murphy B, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. *J Clin Oncol* 2005;23:3562-7.
7. Burtness B, Goldwasser MA, Flood W, et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. *J Clin Oncol* 2005;23:8646-54.
8. Clavel M, Vermorken JB, Cognetti F, et al. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of

- the EORTC Head and Neck Cancer Cooperative Group. *Ann Oncol* 1994;5:521-6.
9. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. *N Engl J Med* 2008;359:1116-27.
 10. Ferris RL, Blumenschein G, Jr., Fayette J, et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. *N Engl J Med* 2016;375:1856-67.
 11. Cohen EEW, Soulieres D, Le Tourneau C, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. *Lancet* 2019;393:156-67.
 12. Burtneß B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. *Lancet* 2019;394:1915-28.

doi: 10.21037/tro.2020.03.02

Cite this article as: Kiyota N, Imamura Y. New first-line treatment for recurrent or metastatic squamous cell carcinoma of head and neck: does one size fit all? *Ther Radiol Oncol* 2020;4:5.